A multi‐institutional validation study on the prediction of high‐risk pancreatic intraductal papillary mucinous neoplasms showed that sFasL was significantly overexpressed in all 60 high‐risk patients.[60] Further, abnormally elevated sFasL is a key predictive marker for the identification of patients with autoimmune lymphoproliferative syndrome.[61] Based on this, we determined the levels of mFasL and sFasL in BON‐1 and QGP‐1 cells using flow cytometry and ELISA assays, respectively. The gene discussed is FASLG; the disease is pancreatic intraductal papillary-mucinous neoplasm.